We evaluated the role of thrombin-specific anticoagulation with bivalirudin in such patients. Bivalirudin plus a glycoprotein IIb/IIIa inhibitor, as compared with heparin plus a glycoprotein IIb ...

UCB-Bioproducts (UCB-Bio) today announced that it will provide commercial quantities of bivalirudin, the active pharmaceutical ingredient (API) for The Medicine Company's (NASDAQ: MDCO ...

Medicines Co. said the U.S. Patent and Trademark Office granted a one-year extension for the patent on its anticoagulant drug Angiomax, which accounts for almost all the company’s revenue.

CHICAGO (Reuters) - As the commonly used blood thinner heparin is recalled around the world and some doctors worry about shortages, researchers say the anti-clotting drug Angiomax works just as well.

Kong, MD, and Daniel B. Mark, MD (Duke Clinical Research Institute), who noted, "Bivalirudin appears to provide health benefits similar to existing therapies but for less money--a "win" for all ...

But in Medicines Co.'s case, the full-court press isn't for reform, but for something much more specific: a patent extension on its anti-coagulant Angiomax. Medicines applied for a standard patent ...

The chemistry and pharmacology, pharmacokinetics, pharmacodynamics, adverse effects, drug interactions, dosing and administration, and pharmacoeconomics of bivalirudin are reviewed; clinical ...

Medicines Co. won a court ruling that may provide an additional four years of patent protection on its anticoagulant drug Angiomax, which accounts for almost all company revenue. The shares rose ...

Bivalirudin was recognized by the expert panel as having both the highest strength of recommendation and level of evidence from clinical research (Class I, level of evidence B) of any intravenous ...

CHICAGO, March 29 (Reuters) - As the commonly used blood thinner heparin is recalled around the world and some doctors worry about shortages, researchers say the anti-clotting drug Angiomax works ...